Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

Abstract Background Anti-tumor necrosis factor (anti-TNF) agents are an effective, but costly, treatment for spondyloarthritis (SpA). Worldwide, multiple sets of access criteria aim to restrict anti-TNF therapy to patients with specific clinical characteristics, yet the influence of access criteria...

Full description

Bibliographic Details
Main Authors: Stephanie Harvard, Daphne Guh, Nick Bansback, Pascal Richette, Alain Saraux, Bruno Fautrel, Aslam Anis
Format: Article
Language:English
Published: BMC 2017-09-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Cost-effectiveness
Anti-TNF
Biologics
Pharmaceutical policy
Spondyloarthritis
Online Access:http://link.springer.com/article/10.1186/s12962-017-0081-8

Internet

http://link.springer.com/article/10.1186/s12962-017-0081-8

Similar Items